STOCK TITAN

Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) is scheduled to release its Q2 2022 financial results after the market closes on August 3, 2022. The management will hold a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast on the company's website. Glaukos focuses on innovative therapies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012.

Positive
  • Scheduled release of Q2 2022 financial results indicating company transparency for investors.
  • Management will discuss results in a timely conference call, providing direct insights.
  • Ongoing commitment to innovation in ophthalmic medical technology.
Negative
  • None.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 3, 2022.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos Corporation release its Q2 2022 financial results?

Glaukos Corporation will release its Q2 2022 financial results after the market closes on August 3, 2022.

What time is the conference call for Glaukos Corporation's Q2 results?

The conference call for Glaukos Corporation's Q2 results is scheduled for 1:30 p.m. PT on August 3, 2022.

Where can I access the webcast for Glaukos Corporation's financial results?

The webcast for Glaukos Corporation's financial results can be accessed on the company's investor relations website.

What is Glaukos Corporation known for?

Glaukos Corporation is known for developing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, particularly through its pioneering of Micro-Invasive Glaucoma Surgery (MIGS).

Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Latest News

GKOS Stock Data

7.93B
53.37M
3.19%
101.17%
5.1%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ALISO VIEJO